Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.

ABSTRACT:

Background

Individuals with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) have high plasma total homocysteine (tHcy) levels, which may be a risk factor for cognitive impairment. Whether treatment with high-dose B vitamins to decrease high tHcy levels improves cognition in persons with kidney disease is unknown.

Study design

Randomized controlled trial.

Setting & participants

A substudy of 659 patients (mean age, 67.3 +/- 11.7 years) who participated in a randomized double-blind clinical trial 5 years in duration conducted in 36 US Department of Veterans Affairs medical centers of the effect on all-cause mortality of vitamin-induced lowering of plasma tHcy level. 236 (35.8%) were treated by using dialysis (ESRD) and 423 (64.2%) had a Cockcrof

SUBMITTER: Brady CB 

PROVIDER: S-EPMC2748786 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature